Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...

Part of that involves looking at the #fundamentals, but half of the disclosure comes from looking at price action.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

Thankfully the symbols they use are (mostly) universal, so once you've learned what each represents (as we explain below) you shouldn't have any problems no matter what you find in your laundry basket ...

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 3.06% to $424.26 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.